We are live on ! Find out more

Avalo Therapeutics

AVTX

Market cap $1.01B

18.86 USD

-0.85

4.31%

At close Updated Sep 9, 10:51 AM EDT

1 day

-4.31%

5 days

-0.74%

1 month

-4.6%

3 months

46.2%

6 months

8.95%

Year to date

10.81%

1 year

62.45%

5 years

-99.76%

10 years

-99.83%

About: Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.

Employees: 33

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 11.1%

Neutral 88.9%

Negative 0%

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

WAYNE, Pa., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to six new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 78,000 shares of common stock (the “Options”) as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Avalo Therapeutics: Phase 2 Validation Has Created An IL-1β Franchise

Avalo Therapeutics (AVTX) is now a well-funded, registrational-stage biotech with validated Phase II data for abdakibart in hidradenitis suppurativa (HS). Abdakibart demonstrated statistically significant HiSCR75 response rates and clean safety, with monthly dosing and efficacy across both biologic-experienced and naive patients. AVTX's $472M cash position secures operations into 2029, reducing near-term dilution risk and enhancing negotiating leverage for Phase 3 and beyond.

Avalo Therapeutics: Phase 2 Validation Has Created An IL-1β Franchise

Avalo Therapeutics to Participate in Upcoming Investor Conferences

WAYNE, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences:

Avalo Therapeutics to Participate in Upcoming Investor Conferences

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

WAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced business updates and financial results for the second quarter of 2026.

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

Avalo Therapeutics to Participate in the BTIG Biotechnology Conference

WAYNE, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that Dr. Garry Neil, Chief Executive Officer of Avalo, will participate in the “Honing in on Hidradenitis” panel at the virtual BTIG Biotechnology Conference on Wednesday, July 29, 2026, at 10:30 am ET. Management will also host one-on-one investor meetings during the conference.

Avalo Therapeutics to Participate in the BTIG Biotechnology Conference

Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum

WAYNE, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that management will host one-on-one investor meetings during the Leerink Partners Therapeutics Forum on July 15, 2026, in Boston.

Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum

Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes

WAYNE, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that it will be added to the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 26, 2026.

Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes

Avalo Therapeutics Appoints Ron Philip to Board of Directors

WAYNE, Pa., June 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced the appointment of Ron Philip to its Board of Directors. Mr. Philip brings more than 30 years of biopharmaceutical leadership to the Board, with a deep background in commercial and strategic execution, including guiding multiple companies through product launches and billion dollar exits.

Avalo Therapeutics Appoints Ron Philip to Board of Directors

Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody

WAYNE, Pa., June 16, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the advancement of AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody (mAb) with the potential for development in hidradenitis suppurativa (HS) as well as additional inflammatory disorders.

Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody

Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

WAYNE, PA., May 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that the Company granted an inducement award consisting of an option to purchase 34,000 shares of its common stock to one new employee (the “Option”). The award was approved by the Compensation Committee of the Board of Directors as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

See News Rankings

Price charts implemented using Lightweight Charts™